About Us

We are the world’s pioneer in developing a “beating-heart” surgical system for hypertrophic cardiomyopathy.

The Vass M1 system breaks conventional barriers by enabling minimally invasive septal myectomy without cardioplegia or cardiopulmonary bypass—offering a safer, more efficient, and less traumatic treatment option for patients.

  • Over 7Years

    Dedicated to Research & Development

  • More than1,000cases

    Clinically Proven Success

  • 29Patents Worldwide

    Globally Approved Innovations

  • 100%ndependently Developed Technology

    Leading the world in HCM innovation

  • Clinical Application

    Clinical Application

    Vass M1 has been implemented in leading hospitals across China and is widely used in complex HCM surgeries. 
     
    Surgeons report stable operation, improved efficiency, faster patient recovery, and significantly reduced complications.
  • Our Team

    Our Team

    Our team is composed of cardiac surgeons, biomedical engineers, and regulatory specialists with extensive experience and strong backgrounds. We are committed to transforming complex clinical needs into practical surgical innovations.
Company Milestone

In 2019

Founded in Optics Valley, Wuhan

2020-2021

Completed product prototyping and animal studies

In 2022

Completed first clinical application

2023-2024

Nationwide multi-center clinical rollout

2025-2026

Completion of multi-center randomized controlled clinical trials

In 2019
2020-2021
In 2022
2023-2024
2025-2026
  • Our Culture

    We champion a culture of “rigor, integrity, and practicality,” encouraging interdisciplinary collaboration and striving to develop original medical devices with real clinical value.
  • Our Mission

    To translate clinical innovation into practice.
    We aim to advance minimally invasive cardiac surgery and offer better treatment options to HCM patients worldwide.
Treatment Overview
The Vass M1 system is suitable for both obstructive and non-obstructive HCM patients requiring surgical intervention. It enables precise septal resection while the heart is still beating—significantly reducing operative risk and trauma, and accelerating recovery.
  • Research & Development

    Vass Medical maintains a clinician-driven R&D approach, partnering with top-tier hospitals in China for multi-center studies to continuously refine performance and expand indications.
  • Clinical Collaboration

    We warmly welcome hospitals, physicians, and distribution partners around the world to collaborate in bringing this breakthrough technology to more patients globally.
Join Us
Join us in building a pioneering force in cardiac surgery. 
We are hiring across multiple roles including R&D, clinical affairs, regulatory, and international business.

Please send your CV to:“contact@vassmedical.com”

Contact Us
We welcome you to contact us to schedule a system demo, discuss clinical collaboration, or explore international partnership opportunities.
Company Address:Optics Valley Biomedical Device Park,East Lake High-Tech Development Zone, Wuhan, China

Email:contact@vassmedical.com